Veracyte stock price target lowered to $28 from $29 at Morgan Stanley

Veracyte (NASDAQ:VCYT) reported a robust Q2 2025, significantly beating analyst expectations with EPS of $0.44 and revenue of $130.2 million, prompting the company to raise its 2025 guidance. Despite this strong performance and a reiterated Outperform rating from William Blair, Morgan Stanley maintained an Underweight rating and slightly lowered its price target to $28.00, citing that meaningful upside from Veracyte's promising pipeline is a 2027+ dynamic. The stock experienced an after-hours decline, suggesting investor focus on the longer-term realization of growth potential despite immediate positive results.

Analysis

Veracyte (VCYT) has demonstrated significant operational strength in its second-quarter 2025 results, posting an earnings per share of $0.44, which represents a 300% surprise over the $0.11 consensus estimate. Revenue also surpassed expectations, coming in at $130.2 million against a forecast of $121.1 million, driven by continued momentum in its Decipher and Afirma product lines. This robust performance prompted management to raise its full-year 2025 guidance. However, the market and analyst sentiment present a conflicted picture. While William Blair reiterated its Outperform rating, Morgan Stanley maintained its Underweight rating and trimmed its price target to $28.00 from $29.00. The divergence stems from timing; Morgan Stanley acknowledges the promising pipeline but posits that a "meaningful upside remains a 2027+ dynamic." The stock's decline in after-hours trading, despite the strong beat-and-raise quarter, suggests that investors are currently aligning with this more cautious, long-term outlook, prioritizing the timeline for future pipeline catalysts over immediate financial outperformance.

Key Decisions for Investors

• Investors with a long-term horizon could interpret the after-hours stock decline as a potential entry point, given the company's strong Q2 earnings beat, raised guidance, and promising pipeline.
• Traders and those with shorter time horizons should heed Morgan Stanley's caution and the market's negative reaction, as significant value realization from the pipeline is not anticipated for several years.
• Monitor future management commentary and clinical data releases closely, as progress on the pipeline's development timeline will be the primary catalyst to bridge the gap between current strong performance and future valuation.